60 patents
Page 2 of 3
Utility
B7-H4 antibodies and methods of use thereof
19 Apr 22
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof.
Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
Filed: 23 Aug 18
Utility
Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
19 Apr 22
Methods of identifying and using PSGL-1 antagonists are provided.
Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
Filed: 10 Jan 18
Utility
Antibodies Binding to Vista at Acidic pH
10 Mar 22
The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment.
Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
Filed: 10 Jul 19
Utility
Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment
10 Feb 22
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
Filed: 2 Jul 21
Utility
CD80 Extracellular Domain FC Fusion Proteins for Treating PD-L1 Negative Tumors
3 Feb 22
The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
Susannah D. BARBEE, Thomas BRENNAN, Barbara SENNINO
Filed: 21 Feb 20
Utility
Afucosylated anti-FGFR2IIIB antibodies
1 Feb 22
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated.
Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
Filed: 6 Nov 18
Utility
Anti-FGFR2 Antibody Formulations
13 Jan 22
This disclosure relates to a formulation of an anti-fibroblast growth factor receptor 2 (FGFR2) antibody that, in some embodiments, is capable of being stored as a liquid, for example in a ready-to-use form, and that, in some embodiments, may be administered intravenously such as by intravenous (IV) infusion.
Isaias Prado, Chin-Yi Huang
Filed: 4 Oct 19
Utility
Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
30 Nov 21
Antibodies that bind CSF1R are provided.
Justin Wong, Maximiliano Vasquez
Filed: 8 Jan 20
Utility
CD80 Extracellular Domain FC Fusion Protein Dosing Regimens
4 Nov 21
The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.
Sandeep P. INAMDAR, Kristen PIERCE, Hong XIANG, Susannah D. BARBEE
Filed: 28 Aug 19
Utility
Combination Therapy for Cancer
28 Oct 21
The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.
Sandeep P. INAMDAR, Helen L. COLLINS, Hong XIANG, Xiang ZHANG, Neyssa MARINA
Filed: 7 Apr 21
Utility
Anti-ROR1 antibodies
26 Oct 21
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer.
Brian Wong, Emma Masteller, Cheng Liu, Yiyang Xu, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang
Filed: 17 May 16
Utility
Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
14 Oct 21
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
Filed: 24 Feb 21
Utility
Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
9 Sep 21
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
Filed: 11 Feb 21
Utility
CD80 extracellular domain polypeptides and their use in cancer treatment
24 Aug 21
This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
Filed: 15 Mar 19
Utility
Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
17 Aug 21
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
Filed: 15 May 18
Utility
Enhanced Cytometry for Tissue Characterization and Screening
15 Jul 21
An optical imaging system (100) includes a frame (102) designed to provide mechanical coupling between a first stage (104) and a second stage (106), a sample holding region (108) located on the first stage (104), a lens arrangement, and a sensor array.
Nallakkan ARVINDAN, Stephen MEHI, Guanqing OU
Filed: 23 May 19
Utility
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
13 Apr 21
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
Filed: 18 Jun 15
Utility
B7-H4 Antibodies and Methods and Use Thereof
18 Mar 21
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4.
Charles KAPLAN, Alessandro PALUMBO, Kathy MILLER, Hangil PARK, Nerissa MENDOZA, Majid GHODDUSI
Filed: 28 Aug 20
Utility
B7-H4 Antibody Formulations
11 Mar 21
The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4).
Yong QUAN, Chin-Yi HUANG, Harjeet Singh GANDA
Filed: 19 Aug 20
Utility
B7-H4 Antibody Dosing Regimens
11 Mar 21
The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bid to human B7-H4 to a subject in need thereof, for example, a cancer patient.
Sandeep P. INAMDAR, Helen L. COLLINS, Xiang ZHANG, Hong XIANG
Filed: 19 Aug 20